Clinical Trial Information
Mitsubishi Tanabe Pharma Corporation (herein after MTPC) is working to increase transparency in clinical trial information. For details, please click here to access our Clinical Trial Information Disclosure Policy.
This website provides information related to summaries of clinical trial information, clinical trial summary results, clinical trial data to be shared with researchers, publication, and clinical trial data to be shared with patients.
- Terms of Use
-
The information on this web page is not intended to promote or advertise MTPC products, or to recommend off-label or unapproved use of any product.
MTPC will endeavor to update information regularly on all clinical trials listed here. However, please understand that changes in clinical trial results may not always be reflected immediately in the list of summaries of clinical trial information provided on this web page.
Please note: Each individual patient is unique, and information from a specific clinical trial may be more clinically significant for some patients than for others. This clinical significance should be determined by doctors experienced in treating the specific disease that was targeted in the trial, or by other qualified healthcare professionals. If you are a patient or family member and you have any questions about the relevance of clinical trial results to your specific symptoms, please consult your doctor or other appropriate healthcare professional.
1. Registration of Clinical Trial Information and Disclosure of Results
a. Registration of our clinical trial information, and disclosure of results, to clinical trial registries
MTPC will register and disclose information on publicly-accessible clinical trial registries such as ClinicalTrials.gov, jRCT, EU Clinical Trials Register regarding clinical trials that are being conducted or have been conducted. These three registries can be viewed through the links
below:
b. Disclosure of clinical trial summary results
MTPC will disclose summaries of clinical study reports conducted in patients and is also preparing plain language summary that can be easily understood by patients and other non-specialists.
MTPC will disclose the results from clinical trials in patients that form part of the submission package for products initially approved in the United States, Europe, or Japan (in all areas where MTPC intends to obtain marketing approval) in or after January 2018. Results will not be disclosed if MTPC decides that disclosure may lead to identification of clinical trial participants. Results may not be disclosed under any of the following conditions:
- A third party, such as a company involved in joint development, has not agreed to disclosure.
- Disclosure may interfere with publication in medical journals.
- Disclosure may interfere with the protection of intellectual property rights.
c. List of summaries of clinical trial information
Summary of clinical trial information disclosed on ClinicalTrials.gov, and summary results for each clinical trial are provided in the list of summaries of clinical trial information below.
The list does not contain clinical trial information on jRCT that is written in Japanese.
| Medical Indication or Disease | Phase | Information on ClinicalTrials.gov | Summary results | Summary results in plain language | |
|---|---|---|---|---|---|
| ClinicalTrials.gov Identifier | Study Status | ||||
| Diffuse Large B-Cell Lymphoma | Phase 1, Phase 2 | NCT05658562 (Update Nov 2023) |
Recruiting | ||
| Stable Coronary Artery Disease (CAD), Unstable Angina (Troponin Negative) | Phase 4 | NCT05740371 (Update Feb 2023) |
Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT05568615 (Update Oct 2023) |
Completed | ||
| Healthy Adult Males | Phase 1 | NCT05396235 (Update Jan 2023) |
Completed | ||
| HTLV-1-Associated Myelopathy (HAM) | Phase 1 | NCT05240612 (Update Sep 2023) |
Active, not recruiting | ||
| Systemic Sclerosis | Phase 3 | NCT05198557 (Update Sep 2023) |
Recruiting | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT05151471 (Update Oct 2023) |
Terminated | ||
| SARS-CoV-2 Infection COVID-19 |
Phase 1, Phase 2 | NCT05065619 (Update May 2023) |
Terminated | ||
| Painful Diabetic Peripheral Neuropathy | Phase 2 | NCT05123196 (Update Nov 2022) |
Completed | ||
| Erythropoietic Protoporphyria: EPP, X-Linked Protoporphyria: XLP | Phase 3 | NCT05005975 (Update Jul 2023) |
Active, not recruiting | ||
| Healthy Adult Subjects | Phase 1 | NCT04776135 (Update May 2021) |
Completed | ||
| Spinal Cord Injury | Phase 2 | NCT04683848 (Update Sep 2023) |
Recruiting | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT04577404 (Update Oct 2023) |
Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT04569084 (Update Oct 2023) |
Terminated | ||
| Diffuse Cutaneous Systemic Sclerosis: dcSSc | Phase 2 | NCT04440592 (Update May 2023) |
Active, not recruiting | ||
| Erythropoietic Protoporphyria: EPP, X-Linked Protoporphyria: XLP | Phase 3 | NCT04402489 (Updated May 2023) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 1 | NCT04254913 (Update Oct 2020) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 2 | NCT00628212 (Update May 2013) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT00998881 (Update Feb 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT00974090 (Update May 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT01026194 (Update Jan 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT02314637 (Update Aug 2015) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT01072331 (Update Apr 2013) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT01301833 (Update Nov 2015) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 4 | NCT02081599 (Update Sep 2017) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT02916706 (Update Mar 2022) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT02924064 (Update Mar 2022) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 2 | NCT00971243 (Update Sep 2014) | Completed | ||
| Acute Ischemic Stroke: AIS | Phase 4 | NCT00412867 (Update Jan 2018) | Completed | ||
| Schizophrenia | Phase 2 | NCT00862992 (Update Apr 2021) | Completed | ||
| Schizophrenia | Phase 3 | NCT01625000 (Update Apr 2021) | Completed | ||
| Schizophrenia | Phase 3 | NCT01626872 (Update Apr 2021) | Completed | ||
| Schizophrenia | Phase 3 | NCT01625897 (Update Apr 2021) | Completed | ||
| Schizophrenia | Phase 3 | NCT01626885 (Update Apr 2021) | Completed | ||
| Schizophrenia | Phase 3 | NCT01626859 (Update Apr 2021) | Completed | ||
| Heparin-induced Thrombocytopenia Type II | Phase 2 | NCT00861692 (Update Aug 2016) | Completed | ||
| Immunization; Infection in Healthy Infants | Phase 3 | NCT02992925 (Update Feb 2019) | Completed | ||
| Immunization; Infection in Healthy Infants | Phase 3 | NCT03188692 (Update Feb 2019) | Completed | ||
| Prophylaxis of tetanus, diphtheria, pertussis, poliomyelitis, and bacterial meningitis in Healthy Infants | Phase 3 | NCT03891758 (Update Nov 2020) | Completed | ||
| Prophylaxis of diphtheria, tetanus, and pertussis in Healthy Adolescents | Phase 3 | NCT02118961 (Update Jan 2017) | Completed | ||
| Multiple Sclerosis | Phase 2 | NCT00537082 (Update Apr 2011) | Completed | ||
| Multiple Sclerosis | Phase 2 | NCT00670449 (Update Sep 2013) | Completed | ||
| Chronic Hepatitis C | Phase 1 | NCT00591214 (Update May 2014) | Completed | ||
| Chronic Hepatitis C | Phase 1 | NCT00630058 (Update May 2014) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT00780416 (Update May 2014) | Completed | ||
| Chronic Hepatitis C | Phase 2 | NCT00621296 (Update May 2014) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT00780910 (Update May 2014) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT00781274 (Update May 2014) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT01466192 (Update Nov 2014) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT01468584 (Update Nov 2014) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT01753557 (Update Oct 2016) | Completed | ||
| Chronic Hepatitis C | Phase 3 | NCT01753570 (Update Oct 2018) | Completed | ||
| Chronic Hepatitis C | Phase 1 | NCT01766167 (Update Jan 2017) | Completed | ||
| Chronic Kidney Disease | Phase 3 | NCT00500682 (Update Jun 2022) | Completed | ||
| Chronic Kidney Disease | Phase 3 | NCT00501046 (Update Jun 2022) | Completed | ||
| Diabetic Polyneuropathy | Phase 2 | NCT00307749 (Update Dec 2007) | Completed | ||
| Cerebral Infarction | Phase 4 | NCT00200356 (Update Jan 2013) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT00330681 (Update May 2017) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT00424463 (Update Aug 2018) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT00415519 (Update Dec 2017) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT01492686 (Update Dec 2018) | Completed | ||
| Acute Ischemic Stroke: AIS | Phase 2 | NCT03346538 (Update Sep 2018) | Terminated | ||
| Acute Ischemic Stroke: AIS | Phase 2 | NCT00821821 (Update May 2014) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 3 | NCT04165824 (Update May 2023) | Completed | ||
| Amyotrophic Lateral Sclerosis: ALS | Phase 1 | NCT04176224 (Registration Nov 2019) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 2 | NCT00497198 (Update Jun 2012) | Completed | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia | Phase 3 | NCT00506441 (Update Sep 2014) | Completed | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia | Phase 3 | NCT00772382 (Update Sep 2014) | Completed | ||
| Chronic Kidney Disease With Hyperphosphatemia | Phase 3 | NCT00416520 (Update Nov 2014) | Completed | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia and Dyslipidaemia | Phase 3 | NCT00542386 (Update Oct 2014) | Completed | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia | Phase 3 | NCT00451295 (Update Nov 2011) | Terminated | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia | Phase 3 | NCT00542815 (Update Oct 2014) | Completed | ||
| Chronic Kidney Disease on Dialysis | Phase 3 | NCT00858637 (Update Dec 2014) | Completed | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia in paediatric subjects | Phase 3 | NCT01814904 (Update May 2015) | Terminated | ||
| Chronic Kidney Disease on Dialysis With Hyperphosphatemia in paediatric subjects | Phase 3 | NCT01814917 (Update May 2015) | Terminated | ||
| Chronic Kidney Disease Not on Dialysis With Hyperphosphatemia in paediatric subjects | Phase 3 | NCT01818687 (Update May 2015) | Terminated | ||
| Cerebral Infarction | Phase 3 | NCT00129805 (Update Aug 2008) | Completed | ||
| Cerebral Infarction | Phase 3 | NCT00147303 (Update Apr 2015) | Completed | ||
| Rheumatoid Arthritis | Phase 2 | NCT01143337 (Update Oct 2014) | Completed | ||
| Inflammatory Bowel Disease | Phase 1 | NCT01666327 (Update Sep 2014) | Completed | ||
| Relapsing-remitting Multiple Sclerosis | Phase 2 | NCT01742052 (Update Sep 2016) | Completed | ||
| Relapsing-remitting Multiple Sclerosis | Phase 2 | NCT01890655 (Update Apr 2016) | Completed | ||
| Plaque Psoriasis | Phase 2 | NCT01987843 (Update Dec 2014) | Completed | ||
| Crohn's Disease | Phase 2 | NCT02378688 (Update Oct 2016) | Completed | ||
| Crohn's Disease | Phase 2 | NCT02389790 (Update Sep 2017) | Completed | ||
| Crohn's Disease | Phase 1 | NCT02148185 (Update Sep 2014) | Completed | ||
| Systemic Lupus Erythematosus | Phase 1 | NCT02307643 (Update Jun 2017) | Completed | ||
| Prophylaxis of Haemophilus Influenza Type b in healthy infants | Phase 2 | NCT02140047 (Update Oct 2015) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT02220907 (Update Nov 2018) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT02354222 (Update Nov 2018) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT02354235 (Update Nov 2018) | Completed | ||
| Endometrial Related Pain | Phase 2 | NCT03840993 (Update May 2023) | Completed | ||
| Seasonal Allergic Rhinitis | Phase 1 | NCT03570957 (Update Jan 2019) | Completed | ||
| Spinal Cord Injury | Phase 1 | NCT04096950 (Update May 2023) | Completed | ||
| Diabetic Nephropathy | Phase 2 | NCT01756703 (Update Feb 2015) | Completed | ||
| Diabetic Nephropathy | Phase 2 | NCT01756716 (Update Feb 2015) | Completed | ||
| Diabetic Nephropathy | Phase 1, Phase 2 | NCT01889277 (Update Jan 2015) | Completed | ||
| Diabetic Nephropathy | Phase 1, Phase 2 | NCT02205372 (Update Sep 2015) | Completed | ||
| Diabetic Nephropathy | Phase 2 | NCT02517320 (Update Mar 2017) | Completed | ||
| Diabetic Nephropathy | Phase 2 | NCT02676401 (Update Sep 2017) | Completed | ||
| Non-Alcoholic Steatohepatitis: NASH | Phase 2 | NCT02923154 (Update Sep 2019) | Completed | ||
| Tardive Dyskinesia | Phase 2, Phase 3 | NCT03176771 (Update Sep 2023) | Completed | ||
| Osteoarthritis, Knee / Osteoarthritis, Hip | Phase 2, Phase 3 | NCT03245008 (Update May 2023) | Completed | ||
| Prophylaxis of Rotavirus Vaccine in Healthy Adults, Toddlers and Infants | Phase 1 | NCT03507738 (Update Aug 2019) | Completed | ||
| Anemia; Non-dialysis Dependent Chronic Kidney Disease | Phase 3 | NCT03329196 (Update Aug 2021) | Completed | ||
| Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease | Phase 3 | NCT03402386 (Update Aug 2021) | Completed | ||
| Anemia; Hemodialysis Dependent Chronic Kidney Disease | Phase 3 | NCT03439137 (Update Aug 2021) | Completed | ||
| Anemia; Hemodialysis Dependent Chronic Kidney Disease | Phase 3 | NCT03461146 (Update July 2021) | Completed | ||
| Erythropoietic Protoporphyria: EPP | Phase 2 | NCT03520036 (Update May 2023) | Completed | ||
| Menopause Hot Flashes | Phase 2 | NCT03291067 (Update May 2023) | Completed | ||
| Vasomotor Symptoms: VMS | Phase 2 | NCT03541200 (Update May 2023) | Completed | ||
| Vasomotor Symptoms: VMS | Phase 1 | NCT02803268 (Update Feb 2017) | Completed | ||
| Painful Diabetic Peripheral Neuropathy | Phase 2 | NCT03172598 (Update Aug 2018) | Completed | ||
| Rheumatoid Arthritis | Phase 3 | NCT00691028 (Update Mar 2014) | Completed | ||
| Crohn's Disease | Phase 3 | NCT00805766 (Update Feb 2018) | Completed | ||
| Pediatric Crohn's Disease | Phase 3 | NCT01580670 (Update Jul 2019) | Completed | ||
| Pediatric Ulcerative Colitis | Phase 3 | NCT01585155 (Update Nov 2019) | Completed | ||
| Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin | Phase 3 | NCT01596335 (Update Oct 2018) | Completed | ||
| Behcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease | Phase 3 | NCT01532570 (Update Dec 2016) | Completed | ||
| Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma | Phase 3 | NCT01680159 (Update Mar 2017) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 1, Phase 2 | NCT00707954 (Update Apr 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 2 | NCT01022112 (Update Jun 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT01413204 (Update Jun 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 3 | NCT01387737 (Update Jun 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 1 | NCT01512849 (Update Jun 2014) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 4 | NCT02220920 (Update Dec 2016) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 4 | NCT02227849 (Update Apr 2019) | Completed | ||
| Type 2 Diabetes Mellitus | Phase 4 | NCT02622113 (Update Apr 2019) | Completed | ||
| Diabetic Nephropathy | Phase 3 | NCT03436693 (Update Sep 2021) | Completed | ||
| Perennial Allergic Rhinitis in Pediatric Patients | Phase 3 | NCT01425632 (Update Dec 2015) | Completed | ||
| Perennial Allergic Rhinitis in Pediatric Patients | Phase 3 | NCT01900054 (Update Apr 2016) | Completed | ||
| Atopic Dermatitis in Pediatric Patients | Phase 3 | NCT01840605 (Update May 2018) | Completed | ||
| Perennial Allergic Rhinitis in Pediatric Patients | Phase 3 | NCT01861522 (Update Dec 2015) | Completed | ||
2. Sharing Clinical Trial Data with Researchers
When requested by a qualified researcher in the field of science or medicine, MTPC will share clinical trial data that was collected from individual patients in a clinical trial with that researcher after a review committee of experts determines that such sharing is appropriate. Such clinical data will always be anonymized before sharing. MTPC will not share data that MTPC feels may place the patient at risk of being identified.
MTPC will share patient data from clinical trials in patients that form part of the submission package for products initially approved in the United States, Europe, or Japan (in all areas where MTPC intends to obtain marketing approval) in or after January 2018. Please use the following link for other conditions and limitations.
https://vivli.org/ourmember/mitsubishi-tanabe-pharma/
Researchers: Please use the link below to request data sharing.
3. Publication of Clinical Trial Results
MTPC in a timely manner, will endeavor to provide relevant presentations at scientific meetings, or publications in scientific journals, of the clinical trial results where results are considered to be of significant medical importance. When such an article is published, MTPC will cite the publication on publicly accessible clinical trial registries.
4. Sharing Clinical Trial Results with Patients Who Participate in Clinical Trials
MTPC plans to share personal patient results from clinical trials individually with each clinical trial participant. This information-sharing program is currently in the planning stages.
- Questions
-
If you have any questions about disclosure of clinical trial information, please email us: